| Metric | Value ($ M) |
|---|---|
| Revenue | 6.56 |
| Total Income | 6.56 |
| Expenditure | 115.10 |
| PBT | — |
| Net Profit | -98.54 |
| OPM | — |
| NPM | — |
| EPS | -1.11 |
IDEAYA Biosciences Reports Q1 2026 Financial Results
05 May 2026 · 5 May, 3:43 pm
Summary
IDEAYA Biosciences reported its financial results for the first quarter ended March 31, 2026. The company's Phase 2/3 registrational trial of darovasertib combination met its primary endpoint, and IDEAYA plans to initiate the RTOR submission process in May, targeting NDA filing in H2 2026. As of March 31, 2026, IDEAYA had approximately $973 million in cash, cash equivalents, and marketable securities. The net loss for the three months ended March 31, 2026, was $98.5 million.
Key Highlights
- 1
IDEAYA's Phase 2/3 registrational trial (OptimUM-02) of darovasertib combination met its primary endpoint.
- 2
The company plans to initiate RTOR submission process in May, targeting NDA filing in H2 2026.
- 3
IDEAYA had approximately $973 million in cash, cash equivalents, and marketable securities as of March 31, 2026.
- 4
Collaboration revenue for the three months ended March 31, 2026, totaled $6.6 million.
- 5
Research and development expenses for the three months ended March 31, 2026 totaled $95.7 million.
- 6
The net loss for the three months ended March 31, 2026, was $98.5 million.
Management Comments
Yujiro S. Hata
This was a transformational quarter for IDEAYA, with positive topline results from the OptimUM-02 registrational trial in first line HLA*A2-negative metastatic uveal melanoma to enable the company’s first NDA submission for potential U.S. accelerated approval. We look forward to a catalyst rich second half of 2026, including targeted clinical data updates for the darovasertib combination in HLA*A2-positive mUM, IDE849 in DLL3-positive solid tumors, and IDE034, our potential first-in-class B7H3/PTK7 bispecific TOP1 ADC, in multiple large solid tumor indications. Finally, clinical dose escalation is advancing rapidly for our potential first-in-class KAT6/7 dual inhibitor, IDE574, and our PRMT5 inhibitor, IDE892, with the goal of initiating clinical expansion and combination trials with IDE892 in MTAP-deleted PDAC and NSCLC in the second half of this year.”
Informational and educational content only. Not investment advice.